Adrenaline During Resuscitation From Pulseless Electrical Activity

Sponsor

St. Olavs Hospital (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT04149730

Collaborator

Norwegian University of Science and Technology (Other), University of Pennsylvania (Other)

120

Enrollment

Locations

37.4

Anticipated Duration (Months)

Patients Per Site

1.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a prospective observational study at St. Olavs hospital in Norway. Data are gathered from defibrillators that have been in use during resuscitation from cardiac arrest. Aim is to investigate the changes in electrocardiograms (ECG) during resuscitation from pulseless electrical activity (PEA), which is a type of cardiac arrest. ECG changes may be useful as a prognostic marker during resuscitation from PEA. In addition the researchers will describe the effect of adrenaline and chest compressions on clinical state transitions during resuscitation from pulseless electrical activity. Clinical state transitions are changes between different types of cardiac arrest. This study is expected to increase our understanding of the dynamics during treatment of cardiac arrest.

Condition or Disease	Intervention/Treatment	Phase
Heart Arrest

Study Design

Study Type:

Observational

Anticipated Enrollment :

120 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Adrenaline During Resuscitation From Pulseless Electrical Activity

Actual Study Start Date :

Mar 20, 2019

Anticipated Primary Completion Date :

May 1, 2022

Anticipated Study Completion Date :

May 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Patients with primary PEA. Patients at St. Olavs hospital who suffer cardiac arrest and pulseless electrical activity (PEA) as primary rhythm during 2018-2021. 120 episodes from St. Olavs hospital were collected previously (2010-2013). In addition 200 cases will be available from the hospital of The University of Pennsylvania, Philadelphia, USA.

Outcome Measures

Primary Outcome Measures

QRS frequency [Every 3 minutes from start till end of cardiopulmonary resuscitation]
Measurement of RR intervals in milliseconds.
QRS width [Every 3 minutes from start till end of cardiopulmonary resuscitation]
Measurement of the width of QRS complexes in milliseconds
Changes of clinical states [Every 3 minutes from start till end of cardiopulmonary resuscitation]
changes of clinical states (for example from Pulseless electrical activity to Ventricular fibrillation) during treatment of cardiac arrest.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria: Cardiac arrest among hospitalized patients presenting with PEA as the primary rhythm.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104
2	St Olavs Hospital	Trondheim		Norway

Sponsors and Collaborators

St. Olavs Hospital
Norwegian University of Science and Technology
University of Pennsylvania

Investigators

Study Director: Eirik Skogvoll, md prof, St. Olavs Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

St. Olavs Hospital

ClinicalTrials.gov Identifier:

NCT04149730

Other Study ID Numbers:

2019/785

First Posted:

Nov 4, 2019

Last Update Posted:

Nov 8, 2021

Last Verified:

Nov 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by St. Olavs Hospital

Epinephrine

Pulseless electrical activity

Additional relevant MeSH terms:

Heart Arrest

Study Results

No Results Posted as of Nov 8, 2021